Mar 31, 2025 3:45pm EDT Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results
Mar 18, 2025 8:45am EDT Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain
Mar 13, 2025 9:00am EDT Dogwood Therapeutics, Inc. Announces Pricing of $4.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
Mar 12, 2025 8:30am EDT Dogwood Therapeutics, Inc. Announces Conversion of Existing $19.5M in Debt to Equity, Strengthening Balance Sheet Moving Forward
Jan 21, 2025 9:15am EST Dogwood Therapeutics Announces Patient Dosing in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy Induced Neuropathy (CINP) to Commence First Quarter of 2025
Nov 18, 2024 8:45am EST Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study
Oct 31, 2024 9:15am EDT Dogwood Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Thursday, November 7, 2024
Oct 30, 2024 9:15am EDT Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Oct 07, 2024 7:05am EDT Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”)
